Tagged with OP

Global With advances in technology, an increasing number of stable peptide-based therapeutics are being brought to market today across a wide range of therapeutic areas. Through expert insight, we explain why the peptide field is generating so much excitement, outline some of the most significant recent breakthroughs and big-ticket investments, and…

Turkey While supporters of Turkey’s localization policy for pharmaceuticals implemented in 2016 applaud the changes it has brought, its opponents are awaiting a much-anticipated report by the World Trade Organization that could put an end to the policy and have global repercussions.   Five years after the launch of Turkey’s localization…

Denmark Zealand Pharma’s Emmanuel Dulac, fresh from a first US FDA approval for the company’s rescue pen for severe hypoglycaemia in people with diabetes aged 6 years and older, outlines the swift progress that the Danish biotech has made in his two and a half years as CEO. Dulac also highlights…

Italy Speaking recently to PharmaBoardoom, Assobiotec’s Leonardo Vingiani introduced the key dynamics shaping the Italian biotech industry today and the issues it still has to overcome to become truly globally competitive.   Strong Fundamentals The association’s latest reporting shows that there are 751 active biotech firms in Italy, with a turnover…

UAE Amgen MEA’s Mohamed Nasser* examines the current pharma commercialisation model, posits how the entire healthcare ecosystem’s rapid and effective response to COVID-19 could be replicable in other disease areas, and makes his predictions for the industry’s future direction.   Probably more than at any other time in history, the last…

Germany The latest news from German pharma, including Bayer’s USD 2 billion acquisition of San Diego’s Vividion Therapeutics; Boehringer Ingelheim’s new investment in a Vienna production facility; BioNTech’s plans to inaugurate an mRNA manufacturing network in Africa; and the termination of the GSK/Merck KGaA cancer drug partnership.   German drug giant…

Italy Assobiotec’s Leonardo Vingiani introduces the key trends shaping the Italian biotech ecosystem today, the steps that the country’s government have taken to foster life sciences innovation, and the areas in which Italian biotechs truly excel globally.   Italy and its researchers have created a good environment for science. However, the…

USA Susan L. Lang outlines how pharma companies can navigate drug formulary exclusions, numbers of which have been rising in recent years, and ensure that newly FDA approved medicines can make it to consumers.   The pipeline for new therapies at the Food and Drug Administration mostly consists of novel brand…

Canada In conversation in the October edition of DIA’s Global Forum magazine, Canadian Agency for Drugs and Technologies in Health (CADTH) CEO Suzanne McGurn highlights how the work of HTA bodies like CADTH has evolved, the most significant challenges in their work, international collaboration, and RWE integration.   Health technology assessment…

Japan Writing in the October edition of DIA’s Global Forum magazine, Chief Executive of Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Yasuhiro Fujiwara outlines how his agency has begun to utilise real-world data (RWD) and real-world evidence (RWE) in its regulatory decision-making processes and how this will evolve moving forward.  …

Denmark Copenhagen Capacity is Greater Copenhagen’s official organization for investment, promotion, and business development. Its CEO/managing director, Asbjørn Overgaard, outlines the fundamentals attracting life sciences firms to the region, stakeholders’ key investment concerns, and the work still to be done on closer alignment with neighbouring Sweden.   Our goals are threefold:…

Global Shawview Consulting’s Brendan Shaw examines the WHO’s recently released updated Essential Medicines List. Shaw highlights some of the key trends and new inclusions in the List, why pricing and transparency are hotter topics than ever, and how pharma can incorporate this important document and its implications into their strategies for…